---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-109571"
form_type: "8-K"
ticker: "KYNB"
cik: "0000921299"
company_name: "KYNTRA BIO, INC."
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T12:16:33.153286+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# FibroGen receives China SAMR approval for sale of China business to AstraZeneca; closing expected in Q3 2025

## Summary
- China State Administration for Market Regulation decided not to prohibit AstraZeneca's acquisition of FibroGen China.
- Transaction includes all equity of FibroGen International (Hong Kong) Ltd. and roxadustat assets in China.
- Closing expected in Q3 2025, subject to customary closing conditions and deliverables.
- FibroGen retains roxadustat rights in US, Canada, Mexico, and other non-AstraZeneca/Astellas territories.

## SEC filing metadata
- accession: 0000950170-25-109571
- form_type: 8-K
- ticker: KYNB
- cik: 0000921299
- company_name: KYNTRA BIO, INC.
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/921299/000095017025109571/0000950170-25-109571-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/921299/000095017025109571/fgen-20250818.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-109571
- JSON: https://secwatch.observer/filing/0000950170-25-109571.json
- Plain text: https://secwatch.observer/filing/0000950170-25-109571.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.